Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod

Rimas V. Lukas*, Csaba Juhász, Derek A. Wainwright, Charles David James, Eugene Kennedy, Roger Stupp, Maciej S. Lesniak

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Introduction: Glioblastoma (GBM) is the most frequent and aggressive primary tumor of the central nervous system, accounting for over 50% of all primary malignant gliomas arising in the adult brain. Even after surgical resection, adjuvant radiotherapy (RT) and temozolomide (TMZ) chemotherapy, as well as tumor-treating fields, the median survival is only 15–20 months. We have identified a pathogenic mechanism that contributes to the tumor-induced immunosuppression in the form of increased indoleamine 2,3 dioxygenase 1 (IDO1) expression; an enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn). However, real-time measurements of IDO1 activity has yet to become mainstream in clinical protocols for assessing IDO1 activity in GBM patients. Methods: Pre-treatment and on-treatment α-[ 11 C]-methyl-l-Trp (AMT) positron emission tomography (PET) with co-registered MRI was performed on patients with recurrent GBM treated with the IDO1 pathway inhibitor indoximod (D1-MT) and TMZ. Results: Regional intratumoral variability of AMT within enhancing and non-enhancing tumor was noted at baseline. On treatment imaging revealed decreased regional uptake suggesting IDO1 pathway modulation with treatment. Conclusions: Here, we have validated the ability to use PET of the Trp probe, AMT, for use in visualizing and quantifying intratumoral Trp uptake in GBM patients treated with an IDO1 pathway inhibitor. These data serve as rationale to utilize AMT-PET imaging in the future evaluation of GBM patients treated with IDO1 enzyme inhibitors.

Original languageEnglish (US)
Pages (from-to)111-120
Number of pages10
JournalJournal of Neuro-Oncology
Issue number1
StatePublished - Jan 15 2019


  • 1-MT
  • AMT
  • Biomarker
  • Glioblastoma
  • IDO
  • Indoximod
  • PET

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod'. Together they form a unique fingerprint.

Cite this